Evonetix Ltd

Evonetix Ltd, based in the UK, specializes in innovative gene synthesis technology, transforming the engineering biology landscape with a platform that enables high-quality, gene-length DNA synthesis at remarkable speed and scale. Evonetix Ltd is a biotechnology company founded in 2015 and headquartered in Cambridge, UK. The company has developed a unique technology for gene synthesis, distinguishing itself in the synthetic biology field. Matthew Hayes founded Evonetix and has a history of innovation in the biotech sector.

The company has secured a total of GBP 20. 00 mn in a SERIES B funding round on January 19, 2023, led by Foresite Capital, with additional participation from several other investors. This funding round represents the entirety of the total amount raised by the company, which now has a current valuation of GBP 89. 385 mn.

Evonetix specializes in a novel gene synthesis technology designed to transform the landscape of engineering biology. Their core offering is a groundbreaking platform that aims to deliver high-quality, gene-length DNA synthesis at unprecedented speed and scale, effectively bringing gene foundries to research laboratories worldwide. This technology addresses critical challenges related to the accessibility of accurate gene-length DNA, essential for advancements in healthcare, sustainable practices, and agricultural innovations. The primary end users of their products include researchers, biopharmaceutical companies, and academic institutions across diverse geographical markets, focusing on North America, Europe, and parts of Asia.

For the most recent fiscal year 2023, Evonetix reported zero revenue with an EBITDA amount of GBP -19,962,671. In January 2023, Evonetix Ltd raised GBP 20. 00 mn in SERIES B funding to accelerate its commercial strategy, making gene synthesis more accessible. The company plans to expand its product offerings and enhance market penetration in North America, Europe, and Asia within the upcoming year.

The funding will be utilized to advance their technology and support entry into new geographic markets, further positioning Evonetix as a vital partner in the scientific community.